Amyloidosis centre steps away from mainstream support

Lead nuclear medicine technologist David Hutt with AGB’s Phil Facey.

The National Amyloidosis Centre at the Royal Free Hospital has become a new customer of Ashby Gorman Baker (AGB).

The centre has provided a diagnostic, staging, monitoring and management advisory service for the national caseload of patients with amyloidosis since it was commissioned by the NHS National Commissioning Group in 1999.  The practice is said to be the world’s largest and most diverse, and has introduced specific services for patients with hereditary and age-related cardiac amyloidosis.

Lead nuclear medicine technologist David Hutt said: “It is always a big step to move away from mainstream service providers but it is essential in today’s environment to get value for money and to ensure our service to patients is of the highest possible quality.”

See the full report on page 17 of the February 2017 issue of RAD Magazine.